INTRODUCTION
cd T cells represent a small population (1%-10%) of the lymphocyte pool. 1 Unlike conventional ab T cells bearing ab T-cell receptors (TCRs), cd T cells function in an MHC-independent manner and play a vital role in the first line of host defense against infectious diseases.
2,3 In humans, two major subsets of cd T cells, Vd 1 and Vd 2 , have been defined based on the d chain usage. Vd 1 T cells bearing Vd 1 -encoded TCRs predominately reside in specific tissues such as intestine and spleen and respond to stress-induced antigens including MHC class 1-related chain A/B and UL16-binding proteins. [4] [5] [6] In contrast, Vd 2 T cells bearing Vd 2 -encoded TCRs account for the major circulating pool of cd T cells and significantly expand in response to phosphoantigens during a variety of infectious diseases. [7] [8] [9] The balance between Vd 1 T cells and Vd 2 T cells is altered in human immunodeficiency virus (HIV)-infected patients, with increasing Vd 1 T cells and a substantial depletion of Vd 2 T cells. [10] [11] [12] [13] Vd 2 T-cell numbers correlate directly with CD4 1 T-cell counts and inversely with viral loads. 14 The capacity of Vd 2 T cells to respond to phosphoantigens, such as isopentenyl pyrophosphate, inversely correlates with HIV-1 disease progression due to the specific depletion of the Vc2Jc1.2 Vd 2 T-cell subpopulation. 12, 15 However, the mechanisms and clinical consequences for this remain unclear.
Given that most Vd 2 T cells are CD4 2 and resistant to HIV infection, 16 the loss of Vd 2 T cells is likely an indirect effect of HIV infection. Following HIV infection, progression to AIDS is typically associated with chronic immune activation that gradually depletes the naïve CD4
1 T-and CD8 1 T-cell pools and subsequently impairs the immune function of HIV-specific CD4 1 and CD8 1 T cells. [17] [18] [19] To date, the contribution of Vd 2 T-cell depletion in chronic immune activation has not been comprehensively investigated in HIV infection. In this study, we performed a comprehensive phenotypic and functional analysis of memory cd T cells in cohorts of Chinese individuals with acute and chronic HIV infection in different stages of progression to define the specificity of Vd 2 T-cell depletion and the functional changes in the cd subsets. Our efforts constitute a critical step toward identifying key mechanisms and clinical consequences of Vd 2 T-cell depletion in HIV infection. Our findings may help elucidate the role that Vd 2 T cells play in HIV pathogenesis and may provide a sound basis on which to consider immune therapies using these cells.
MATERIALS AND METHODS

Study subjects
One hundred and one HIV-infected patients were enrolled in this study. Most of the patients were from the acute HIV infection (Beijing PRIMO) cohort 20, 21 and the chronic HIV infection cohort from 2006-2012, Beijing You'An Hospital, China. HIV infection was defined by HIV-specific antibody, HIV RNA and western blotting (WB). Patients were divided into four groups: an acute HIV infection group (ACUTE), a slow progression group (SP), a fast progression group (FP) and a HAART group (HAART). Acute HIV-infected patients (ACUTE, n517) were defined as negative in the presence of HIV antibody but positive for HIV RNA. 22 The average infection time of acute HIV-infected patients was 59 (59635.38) days. Patients with progressive disease with less than 350 CD4 1 cells/ml and requiring highly active antiretroviral therapy (HAART) according to the WHO recommendation within 2 years after diagnosis were classified as fast progressors (FPs, n521), and those who did not require HAART (greater than 350 CD4
1 cells/ml) within 2 years were defined as slow progressors (SPs, n537). 23 Patients who received HAART therapy, using a first-line regimen of zidovudine, lamivudine and efavirenz were defined as the HAART group (n526). Patients with opportunistic infections or co-infections with tuberculosis, hepatitis B virus or hepatitis C virus were excluded in this study. Twenty-six age-matched healthy subjects were recruited as healthy controls. The characteristics of all patients are described in Table 1 and Table 2 . This study was approved by the Beijing You'An Hospital Research Ethics Committee with written informed consent obtained from each participant. 
Viral load testing
Plasma viral load was analyzed by the Roche Cobas Amplicor 2.0 assay (Roche Diagnostics, Basel, Switzerland), which has a lower limit of detection of 50 copies/ml. Antibodies Phycoerythrin (PE)-conjugated anti-human CD38 (HIT2) monoclonal antibody (mAb), allophycocyanin-conjugated anti-human HLA-DR (L243) mAb, phycoerythrin-cyanine 7 (PE-cy7)-conjugated anti-human CD3 (HIT3a) mAb, peridinin-chlorophyllprotein complex cyanine 5.5 (PerCP-cy5.5)-conjugated antihuman CD27 (O323) mAb and allophycocyanin-conjugated anti-human CD45RA (HI100) mAb were purchased from Biolegend (San Diego, CA, USA). Fluorescein isothiocyanateconjugated anti-human pan TCRcd mAb, PE-conjugated anti-human pan TCRcd (IMMU510) mAb and fluorescein isothiocyanate-conjugated anti-human pan Vd 2 TCR (IMMU389) were purchased from Immunotech (Beckman Coulter, Fullerton, France). Fluorescein isothiocyanate-conjugated anti-human pan Vd 1 TCR (TS8.2) mAb was purchased from Pierce (Rockford, IL, USA). PE-conjugated IL-17A (SCPL1362) mAb and PE-conjugated interferon-c (IFN-c) (B27) mAb were purchased from BD Pharmingen (San Diego, CA, USA). The isotype control mAbs were purchased from the corresponding company, respectively.
Flow cytometry analysis
For surface staining, peripheral blood mononuclear cells were isolated from healthy controls and HIV-infected patients as described previously. 24, 25 Briefly, the cells were washed with PBS containing 1% bovine serum albumin before labeling with specific antibodies. For intracellular staining, cells were incubated with 50 ng/ml phorbol 12-myristate-13-acetate, 1 mg/ml ionomycin and 5 mg/ml Brefeldin A (Sigma, St Louis, MO, USA), followed by fixation, permeabilization and incubation with specific antibodies. Flow cytometry was performed using a FACScan flow cytometer. Data were analyzed using FlowJo software (Version 7.6.2; Tree Star, Inc., Ashland, OR, USA).
Quantification of plasma lipopolysaccharide (LPS), LPSbinding protein (LBP) and soluble CD14 (sCD14) Plasma LPS was quantified using the limulus amebocyte lysate assay (Hycult Biotech, Uden, The Netherlands) as described previously. 26 Briefly, plasma samples from HIV-infected 27 All operations were carried out according to the manufacturer's instructions.
Statistical analysis
Data are presented as the mean6s.d. One-way ANOVA, the Mann-Whitney U test and Spearman's rank-correlation were performed for data analysis using Prism 5.0 software.
RESULTS
HIV infection disrupts the balance of circulating cd T-cell subsets
We performed a series of flow cytometry analyses to compare the proportions of circulating cd T-cell subsets in HIV-infected patients. We found that both the frequency and the absolute number of total peripheral blood cd T cells were not significantly changed among the healthy controls (n520), ACUTE (n512), SP (n522), FP (n517) and HAART (n521) groups (Figure 1a-c) . However, compared with healthy controls, the proportions and the absolute numbers of Vd 1 cd T cells were significantly increased in all HIV-infected groups, with the highest levels in the FP group (Figure 1d and e). In contrast, the proportions and the absolute numbers of Vd 2 cd T cells in all HIV-infected patient groups were significantly decreased compared to healthy controls (Figure 1d and e), but with no significant differences among the ACUTE, SP and FP groups. In addition, the ratios of Vd 1 cd/Vd 2 cd T cells were reversed in all HIV-infected groups (Figure 1f ). Taken together, these results suggest that HIV infection disrupts the balance of circulating cd T-cell subsets, with a specific depletion of Vd 2 cd T cells. Interestingly, our results show HAART treatment did not restore the depletion of Vd 2 cd T cells in HIV-infected patients (Figure 1d and e). , T CM ) was decreased in all HIV-infected patients groups compared with healthy controls (Figure 2c) . We also found a significant decrease in T CM Vd 2 cd T cells in the FP group compared with that of the SP group (Figure 2c) , suggesting the depletion of T CM Vd 2 cd T cells accelerates the progression of HIV disease. However, the frequency of T CM Vd 2 cd T cells in the HAART group was still lower than the healthy controls, indicating that HAART therapy could not restore the T CM Vd 2 cd T cells (Figure 2c) . Further, the effector memory (CD27 2 CD45RA 2 , T EM ) Vd 2 cd T cells were significantly decreased in the acute HIV-infected patients compared with healthy controls. However, no difference was found between the SP group and the FP group (Figure 2d ). Strikingly, we observed a dramatic increase in terminally differentiated effector memory T EMRA Vd 2 cd T cells in all HIV-infected patients, especially in the acute and the FP groups (Figure 2e ). This dynamic change indicates that HIV infection drives the Vd 2 cd T cells toward a terminally differentiated effector phenotype, which subsequently results in the dysfunction of Vd 2 cd T cells.
Elevated activation of cd T cells in HIV-infected patients
Previous studies demonstrate a persistent activation of CD4 1 T cells and CD8 1 T cells in chronic HIV-infected patients. [28] [29] [30] Here, we investigated whether cd T cells were also overactivated in HIV-infected patients with different disease progressions by measuring the expression levels of activation markers CD38 and HLA-DR using flow cytometry. As shown in Figure 3a , levels of CD38 and HLA-DR expressed on cd T cells in HIV-infected patients were significantly higher than in healthy controls. The frequencies of CD38 1 cd T cells and HLA-DR 1 cd T cells were significantly elevated in all HIV-infected groups compared with the healthy controls (Figure 3b and c) . The frequency of CD38 1 HLA-DR 1 cd T cells was also increased in all HIVinfected patients (Figure 3d ). No significant differences were observed in the frequencies of activated cd T cells among the HIV-infected groups (Figure 3b-d) . We then analyzed the correlation of cd T-cell activation with the CD4 1 T-cell counts and the viral loads in HIV-infected patients. The results show that the frequency of CD38 1 cd T cells displayed a negative correlation with the CD4 1 T-cell count, but no correlation with the plasma viral load in HIV-infected patients (Figure 3e-f) . Moreover, we also found significant increases in the expression of CD25 and CD69 on cd T cells 1 cd T cells with (e) CD4 1 T-cell counts and (f) plasma viral loads. (g) Lymphocytes were gated, and the expression of CD25 and CD69 on cd T cells from HCs (n519) and ACUTE (n515) were analyzed by flow cytometry. Comparisons of the frequencies of (h) CD251cd T cells and (i) CD69
1 cd T cells between the HCs and ACUTE groups. Significant differences and P values were calculated by the Mann-Whitney U tests and one-way ANOVA. Correlations were determined by Spearman's rank correlation. *P,0.05, **P,0.01, ***P,0.0001. HC, healthy control.
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Microbial translocation contributes to elevated activation of cd T cells in HIV-infected patients
Microbial translocation contributes to chronic immune activation in HIV-infected patients, especially toward CD4 1 T and CD8 1 T cells. [31] [32] [33] LPS, a marker of microbial translocation, positively correlates with CD8 1 T-cell activation. 27 LBP is a serum glycoprotein that initiates an immune response after recognition of bacterial LPS in vivo.
34 sCD14 in plasma, driven predominantly by microbial translocation, affects the activation status of T cells. 32 Here, we investigated whether microbial translocation contributes to cd T-cell activation in HIVinfected patients.
We measured three biomarkers, LPS, LBP and sCD14, associated with microbial translocation in the plasma samples from healthy controls and the HIV-infected patients with different disease progressions. The results show that plasma LPS was increased in the early stages of HIV disease (ACUTE and SP groups), but decreased in the HAART group (Figure 4a) . Additionally, we found a slight increase in plasma levels of LBP in the SP and HAART groups compared with the healthy controls (Figure 4b ). Plasma levels of sCD14 were significantly elevated in all HIV-infected patients, especially in the FP and HAART groups, compared with healthy controls (Figures 4c) . These data suggest that microbial translocation predominantly HLA-DR 1 cd T cells and sCD14 (Figure 4g and i) . Additionally, no significant correlation was found between any subset of Vd 2 cd T cells and sCD14 levels in untreated HIV-infected patients (Figure 4j-m) . Together, these results suggest that microbial translocation contributes to elevated activation of cd T cells in chronic HIV-infected patients.
Chronic immune activation depletes memory Vd 2 cd T cells in HIV-infected patients
The finding of elevated activation of cd T cells prompted us to investigate whether chronic immune activation contributes to the depletion of Vd 2 cd T cells in HIV-infected patients. We measured CD38 expression on different Vd 2 cd T cell subsets (T naive , T CM , T EM and T EMRA ) by flow cytometry. Our results show the levels of CD38 expression on all Vd 2 cd T-cell subsets were significantly increased in all HIV-infected groups compared with healthy controls (Figure 5a ), indicating that all Vd 2 cd T cells display an elevated activation in HIV-infected patients.
We then analyzed the correlations between the frequencies of Vd 2 cd T-cell subtypes and the proportion of CD38 1 cd T cells in HIV-infected patients. We found no significant correlation between the frequency of T naïve Vd 2 cd T cells and CD38 1 cd T cells (Figure 5b ). Our findings show that the frequencies of T CM Vd 2 cd T cells and T EM Vd 2 cd T cells were negatively correlated to the frequency of CD38 1 cd T cells (Figure 5c and d) . These data suggest that the depletion of memory Vd 2 cd T cells may result from excessive immune activation of cd T cells in HIVinfected patients. Interestingly, we found a positive correlation between the frequency of T EMRA Vd 2 cd T cells and the frequency of CD38 1 cd T cells (Figure 5e ), indicating that HIV infection causes an increase in excessively activated T EMRA Vd 2 cd T cells.
IL-17-producing cd T cells were significantly increased in chronic HIV-infected patients IFN-c and IL-17 are two important immunoregulatory cytokines in innate immunity against virus and intracellular pathogens. 3, 35 The imbalanced production of cytokines by T cells is associated with the activation and exhaustive status of memory T cells in HIV-infected patients. 36 Here, we assessed the production of IL-17 and IFN-c by cd T cells in HIV-infected patients with different disease progressions. After gating on lymphocytes, IL-17 or IFN-c-producing cd T cells were analyzed in the healthy controls, ACUTE, SP, FP and HAART groups (Figure 6a ). We found that the frequency of IL-17-producing cd T cells was increased in the ACUTE and SP groups and significantly increased in the FP groups, compared with the healthy controls (Figure 6b) . Moreover, HAART treatment reduced the frequency of IL-17-producing cd T cells to nearly the same level as in the healthy controls (Figure 6b) . These results suggest that IL-17-producing cd T cells are involved in HIV disease progression. However, no significant differences in IFN-c-producing cd T cells among the healthy controls, ACUTE, SP, FP and HAART groups were found (Figure 6c ). Correlation analysis also showed significant positive correlations between the frequency of IL-17-producing cd T cells and the frequencies of HLA-DR 1 cd T cells (Figure 6e ) and CD38
1 HLA-DR 1 cd T cells (Figure 6f ), but not with the frequency of CD38 1 cd T cells (Figure 6d ). These results suggest that HIV-1 infection directly distorts the production of cytokines in cd T cells and that IL-17-producing cd T cells may play an important role in HIV pathogenesis and disease progression. Figure 6 The balance of cytokine production by cd T cells is disrupted in HIV-infected patients. PBMCs (2310 6 /well) were seeded into 24-well plates, stimulated with PMA (50 ng/ml)/Ion (1 mg/ml) for 6 h before the addition of BFA (10 mg/ml). 
cells but not to (d) CD38
1 cd T cells. Significant differences and P values were calculated by the Mann-Whitney U test. Correlations were determined by Spearman's rank correlation. *P,0.05, **P,0.01. HC, healthy control; Ion, ionomycin; PBMC, peripheral blood mononuclear cell; PMA, phorbol 12-myristate-13-acetate.
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DISCUSSION
The loss of Vd 2 T cells is an early characteristic event in HIV disease progression. In agreement with previous reports, [11] [12] [13] we found that HIV infection caused a significant increase in Vd 1 T cells and a sharp decrease in Vd 2 T cells, leading to an inverted Vd 2 /Vd 1 ratio in all HIV-infected patients, including acute HIV-infected patients, slow progressors and fast progressors. The decrease of Vd 2 cd T cells was positively correlated to the CD4 1 cell count, but not correlated to viral RNA (data not shown), which was different from a previously published paper from China.
14 This discrepancy may be due to the different HIV strains or transmission routes. Consistent with previous data, 37 we show that HAART therapy did not rescue the loss of Vd 2 cd T cells. However, Chaudhry et al. 38 recently reported that prolonged antiretroviral therapy can reconstitute the Vc2 T-cell receptor repertoire. To date, the mechanisms of Vd 2 cd T-cell depletion are not clear. Li 2 ), abundant in peripheral blood, were significantly depleted in fast progressors. T EM Vd 2 cd T cells were only significantly decreased in acute HIV-infected patients. Moreover, we found that HAART treatment could not restore the proportion of T CM Vd 2 cd T cells, although it could restore the proportion of T EM Vd 2 cd T cells to similar levels in healthy controls. In contrast, there was a significant increase in the frequency of T EMRA Vd 2 cd T cells in HIV-infected patients, especially in acute HIV-infected patients and fast progressors compared with healthy controls. These dynamic changes in memory Vd 2 cd T-cell subsets indicates that the Vd 2 cd T cells might be skewed toward an activated and terminally differentiated effector memory phenotype by HIV infection, subsequently resulting in the dysfunction of Vd 2 cd T cells. This finding is not consistent with the conclusion of Boudová et al. 41 that showed that the proportion of T EM Vd 2 T cells was significantly decreased in HAART-treated groups. Given the heterogeneity of the patients assessed in this study, this discrepancy may be ascribed to differences in HIV strain, gender, transmission route and/or disease status.
Chronic immune activation is one of the well-known characteristics of HIV infection and AIDS pathogenesis. 42, 43 Vd 2 T cells are believed to be highly susceptible to activation-induced cell death. 44 In the present study, we found that the expression levels of activation marker CD38 in memory Vd 2 cd T cells were significantly elevated in all HIV-infected patients. Both T CM and T EM Vd 2 cd T cells negatively correlated with CD38 1 cd T cells. Conversely, T EMRA Vd 2 cd T cells positively correlated with CD38
1 cd T cells. These data indicate that immune activation accounts for the loss of memory T CM Vd 2 cd T cells and an increase in the dysfunctional phenotype of T EMRA Vd 2 cd T cells in HIV-infected patients.
Intestinal microbial translocation is believed to contribute to chronic immune activation in HIV disease. 27, 31, 33 Our study results show that microbial translocation marker sCD14 was significantly elevated in the plasma from HIV-infected patients, consistent with previous studies. 45, 46 Moreover, sCD14 showed significant correlation with HLA-DR 1 cd T cells. These findings suggest microbial translocation may partly contribute to the activation of cd T cells.
A growing body of evidence demonstrates that IL-17-producing cd T cells play crucial roles in inflammatory responses against infectious microorganisms. 47, 48 In this study, we found an increase in IL-17 producing cd T cells in HIV-infected patients, particularly in fast progressors. Our results suggest that IL-17 producing cd T cells may participate in HIV pathogenesis. Further, we observed a positive correlation between IL-17 producing cd T cells and HLA-DR 1 or CD38 1 HLA-DR 1 cd T cells. This indicates that the IL-17 signaling pathway may be involved in cd T-cell activation in HIV disease. Further studies on the activation of the IL-17 signaling pathway are needed for a better understanding of the mechanisms of chronic T-cell activation and HIV pathogenesis.
In conclusion, our results demonstrate a dynamic change in memory Vd 2 cd T cells toward an activated and terminally differentiated effector phenotype T EMRA Vd 2 cd T cell, which may account for the dysfunction of Vd 2 cd T cells in HIV disease. The suggestive role of the IL-17 signaling pathway in T-cell activation in this study provides a new clue for further investigations into the mechanisms of chronic immune activation and HIV pathogenesis during HIV infection. PT1  49  103  PT2  87  154  PT3  50  164  PT4  57  108  PT5  19  142  PT6  150  202  PT7  106  281  PT8  180  297  PT9  176  329  PT10  119  232 Abbreviations: HAART, highly activate antiretroviral therapy; PT, patient.
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